SA’s biggest pharmaceutical manufacturer, Aspen Pharmacare, has sold the commercial rights to its thrombosis business in Europe to US-based Mylan for €641.9m , and will use the funds to further reduce its debt, it announced on Tuesday.
Investors welcomed the news, sending its shares up as much as 9.4% during intraday trading before closing 5.42% up at R141.33. The company has a market capitalisation of R64.5bn.A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.
Sverige Senaste nytt, Sverige Rubriker
Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.
Aspen to sell European thrombosis business for €641.9mThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Källa: BDliveSA - 🏆 12. / 63 Läs mer »
MARKET WRAP: Shoprite and Aspen boost JSE as miners lag behindThe rand fell to about a one-week low, nearing R17/$, with the JSE all share paring gains following the release of second-quarter GDP data
Källa: BDliveSA - 🏆 12. / 63 Läs mer »
Aspen to sell European thrombosis business for €641.9mThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Källa: BDliveSA - 🏆 12. / 63 Läs mer »
MARKET WRAP: Shoprite and Aspen boost JSE as miners lag behindThe rand fell to about a one-week low, nearing R17/$, with the JSE all share paring gains following the release of second-quarter GDP data
Källa: BDliveSA - 🏆 12. / 63 Läs mer »